Camidge R, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). IASLC 2018, abstract PL02.03.
Nieuwe tool biedt inzicht in gevolgen borstkanker tot 14 jaar na diagnose
feb 2022 | Borstkanker